CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy.
Pignolet B, Schwab N, Schneider-Hohendorf T, Bucciarelli F, Biotti D, Averseng-Peaureaux D, Outteryck O, Ongagna JC, de Sèze J, Brochet B, Ouallet JC, Debouverie M, Pittion S, Defer G, Derache N, Hautecoeur P, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Berger E, Pelletier J, Rico A, Zéphir H, Laplaud D, Wiertlewski S, Camu W, Thouvenot E, Casez O, Moreau T, Fromont A, Vukusic S, Papeix C, Vermersch P, Comabella M, Lebrun-Frenay C, Wiendl H, Brassat D; BIONAT, SFSEP, and BEST-MS networks.
Pignolet B, et al. Among authors: vukusic s.
Neurology. 2016 Dec 6;87(23):2491-2494. doi: 10.1212/WNL.0000000000003401. Epub 2016 Nov 4.
Neurology. 2016.
PMID: 27815407
Clinical Trial.
No abstract available.